Objective: Glycemic variability (GV) is associated with increased morbidity and mortality in critically ill patients. This study aimed to contribute to the knowledge on the subject and to investigate the situation in our intensive care patient population. Method: Patients who were admitted to the Intensive Care Unit (ICU) between January 2015 and August 2020 were screened using the hospital’s database. The following data were collected: demographic characteristics of the patients, comorbidities, APACHE II scores, SOFA scores, mean amplitude of glycemic excursions (MAGE) based on daily blood glucose measurements from the first day of ICU admission until discharge up to the 28th day of their stay, length of stay (LOS), and 28-day mortality status. Results: In this study, 136 patients were enrolled and divided into high (n=70) and low GV (n=66). No differences were found between the two groups in terms of age, gender, comorbidity, APACHE II, mean SOFA scores, treatments, ICU LOS, and mortality. MAGE was higher in nonsurvivors (78.8 ±32.2) compared to survivors (65.4 ±22.5) (t=-2.78, p= 0.005). Regarding the mortality, the AUC value for GV was 0.611 (p=0.02) for MAGE >61 mg/dl, with a sensitivity of 68.5% and specificity of 50%. Patients were grouped according to GV (MAGE>65) and the presence of diabetes mellitus (DM). Mortality was highest in patients with high GV and without DM (53.3%). Conclusion: In this study, MAGE levels were higher in non-survivors than survivors, and glycemic variability was moderately associated with mortality. Patients with high GV and without DM had a higher mortality rate compared to those with DM.
1 January 2024 in Eurasian Journal of Medical Advances
Objectives: Endometrial cancer is the second most common gynecological cancer worldwide. Despite being usually diagnosed at an early stage with a better prognosis compared to other gynecological cancers, some cases can be aggressive. Obtaining data on independent prognostic factors correlated with survival and recurrence would be beneficial to control the disease and make informed systemic treatment decisions effectively. We aimed to review endometrial cancer's clinical and pathological features and determine the prognostic risk factors. Methods: We conducted a retrospective study on 136 individuals with endometrial cancer who were followed up between 1997 and 2015. Prognostic factors with a p-value of less than 0.15 using the Long-rank test were included in multivariate analysis. Multivariate analysis was performed by the Cox regression test. Results: Significant prognostic factors determining the overall survival in univariate analysis were disease stage, histological grade, age at diagnosis, histological type, lymph node metastasis, lymphatic and vascular invasion, depth of myometrial invasion, cervical stromal invasion, tumor diameter, the positivity of peritoneal cytology, and pre-op serum CA-125 levels. In multivariate analysis, advanced stage and high preoperative CA-125 levels were detected as factors reducing overall survival (p=0.012, p=0.005, respectively). Conclusion: The two most important factors for endometrial cancer survival were stage and pre-op serum CA-125 level, independent of other parameters. As our study was retrospectively done with a limited number of patients, more extensive prospective, randomized studies with a larger number of patients are necessary to apply the information obtained from this study to our clinical practices.
Background: Dysregulation of microRNA expression emerges as a crucial factor in the pathogenesis of autoimmune diseases, and their importance in modulating immune responses and disease progression is evident. Methods: This study investigated the expression patterns of miRNAs in the brain tissues of C57BL/6J mice using the experimental autoimmune encephalomyelitis (EAE) model, which mimics multiple sclerosis (MS). The model was treated with Oenothera biennis oil, a potential therapeutic agent. Results: Our research has revealed a novel and significant likelihood of association between miR‐182‐5p, miR‐200c‐3p, miR‐206‐3p, miR‐429‐3p, miR‐1298‐5p, and diseases resembling the EAE model, such as MS. This groundbreaking discovery could have profound implications in diagnosing and treating autoimmune diseases that mimic the EAE animal model. Conclusions: These miRNAs, identified in our study, might serve as potential therapeutic targets in MS, potentially leading to more effective treatments and improved patient outcomes.